First product from collaboration between RaySearch and TomoTherapy receives FDA clearance

First product from collaboration between RaySearch and TomoTherapy receives FDA
clearance

RaySearch Laboratories AB and TomoTherapy Inc. announced today that the new
software solution SharePlan™ has received 510(k) clearance by the FDA and can
now be market launched.

SharePlan™ is an advanced treatment planning solution that enables transfer of
treatment plans between TomoTherapy® Hi•Art® systems and conventional linear
accelerators. The product uses highly sophisticated algorithms to automatically
generate a selection of deliverable high-quality IMRT plans based on an existing
Hi•Art® plan. This time-saving concept is an important tool for optimizing
patient benefit and throughput at clinics that are introducing a Hi-Art® system
into an environment with existing conventional linear accelerators.

“We put great pride in our collaboration with TomoTherapy and have been working
intensely on this product for little over a year so of course it feels very
rewarding that we now reach the market. Hi•Art® users expect cutting-edge
technological solutions and I am convinced that SharePlan will live up to their
standards. Automatic plan generation is a revolutionary treatment planning
concept that offers unparalleled user-friendliness and has the potential to
dramatically reduce the everyday workload spent on routine tasks,” says Johan
Löf, President of RaySearch.

“Our success is not just based upon delivering the highest quality radiation
therapy,” according to Del Coufal, Vice President of Marketing for TomoTherapy.
“We understand how important it is for TomoTherapy® technology to seamlessly
integrate into a cancer center, regardless of the type of surrounding equipment
the center also uses. By aligning with industry-leading strategic partners like
RaySearch, we are able to make it easy for any center to easily adopt our
revolutionary radiotherapy system.”



ABOUT TOMOTHERAPY
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy®
Hi•Art® treatment system, an advanced radiation therapy system for the treatment
of a wide variety of cancers. The Hi•Art treatment system combines integrated CT
imaging with conformal radiation therapy to deliver sophisticated radiation
treatments with speed and precision while reducing radiation exposure to
surrounding healthy tissue. The company's stock is traded on the NASDAQ Global
Select Market under the symbol TOMO. 

To learn more about TomoTherapy, please visit TomoTherapy.com.



ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have
been released to date and RaySearch's software is used at over 1,300 clinics in
more than 30 countries. In addition, existing license agreements cover more than
15 other products that are scheduled to be launched in the coming years.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the SmallCap segment on the OMX Nordic
Exchange Stockholm. 

For more information about RaySearch, please visit www.raysearchlabs.com.


FOR FURTHER INFORMATION, CONTACT:

TOMOTHERAPY
Del Coufal, VP of Marketing, TomoTherapy Inc.
Telephone: +1 (608) 824 2971
dcoufal@tomotherapy.com

RAYSEARCH
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com